Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan + Endocrine Therapy in HR+/HER2- mBC (SoGreat)
NCT07163481Phase 1Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sacituzumab govitecan in breast cancer (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Treatment-Emergent Adverse Events at 1 year. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07163481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07163481.